跳至主要内容
临床试验/NCT03182985
NCT03182985已完成不适用

The Impact of Time Restricted Feeding (TRF) in Improving the Health of Patients With Metabolic Syndrome

University of California, San Diego2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2017年7月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
35
试验地点
2
主要终点
Mean blood glucose

研究概览

简要总结

The investigators intend to measure the health impact of a dietary intervention known as time restricted feeding (TRF) on patients with metabolic syndrome (three or more of: increased waist circumference, abnormal cholesterol levels, elevated blood pressure, or elevated blood sugar). The investigators will enroll patients with metabolic syndrome who eat for ≥ 14 hours per day and will ask participants to reduce daily oral intake to 10 hours per day. The investigators will assess the impact of this dietary change using measures obtained before and after a 12 week intervention period, including body mass index, blood pressure, various lab parameters and blood sugar levels (assessed using a continuous glucose monitor). The investigators will assess for compliance with TRF using a Smart Phone application (myCircadianClock (mCC) app).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Waist circumference ≥ 102 cm (Men) or ≥ 88 cm (Women).
  • Triglycerides ≥ 150 mg/dL (or on drug treatment for elevated triglycerides).
  • Reduced HDL-C < 40 mg/dL (Men), < 50 mg/dL (Women) (or on drug treatment for reduced HDL-C).
  • Elevated blood pressure, systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg (or treatment with antihypertensive drug with history of hypertension).
  • Elevated fasting glucose ≥ 100 mg/dL (or drug treatment of elevated blood glucose).
  • Age ≥18 years.
  • If patients are on cardiovascular medications (HMG coenzyme A reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive, anti-diabetes drugs), no dose adjustments will be allowed during the study period
  • Own a Smartphone with Apple iOperating System (OS) or Android OS. Baseline eating period is ≥ 14 hours per day.

排除标准

  • Pregnant or breast-feeding.
  • Caregiver for a dependent requiring frequent nocturnal care/sleep interruptions. Shift workers with variable (e.g. nocturnal) hours.
  • Planned international travel during the study period.
  • Active tobacco abuse or history of treatment for alcohol abuse,
  • Known inflammatory and/or rheumatologic disease,
  • Known history of familial hypercholesterolemia,
  • History of major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA))
  • Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria)
  • History of sudden cardiac death (SCD) or implantable cardiac defibrillator (ICD) implantation for any reason,
  • Known history of thyroid or adrenal disease,
  • Any history of malignancy,
  • Known history of type I diabetes,
  • Known history of major immune disease,
  • Eating disorder or bile syndrome,
  • History of cirrhosis
  • History of stage 4 or 5 chronic kidney disease or requiring dialysis
  • History of chronic obstructive pulmonary disease (COPD)
  • Known active infectious diseases,
  • Currently enrolled in a weight-loss or weight-management program,
  • On a special or prescribed diet for other reasons (e.g. Celiac disease),
  • Currently taking any medication that is meant for, or has known effect on, appetite,
  • Any history of surgical intervention for weight management,
  • History of venous thromboembolism.
  • Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness)
  • History of known clotting or bleeding disorder(s)

结局指标

主要结局

Mean blood glucose

时间窗: 12 weeks

Measured using a continuous glucose monitoring (CGM) device

次要结局

  • Insulin, triglycerides, hs-CRP levels(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Pam Taub, MD

Associate Professor of Medicine

University of California, San Diego

研究点 (2)

Loading locations...

相似试验